Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Read more
Sign In
June 16, 20217:55 AM PDTLast Updated 2 months ago
Healthcare & Pharmaceuticals
EU says J&J to miss vaccine supply target in second quarter
Francesco Guarascio

4 minute read
Empty vials of Johnson & Johnson's coronavirus disease (COVID-19) vaccine are seen on a table at a vaccination centre in Ronda, Spain, April 23, 2021. REUTERS/Jon Nazca/File Photo
J&J had committed to delivering 55m doses to EU by end of June
EU worried by shortfall, but on track to meet vaccination goals
EU refuses to use 17 million doses over safety concerns
European regulator says discarded doses might be exported
BRUSSELS, June 16 (Reuters) - Johnson & Johnson (JNJ.N) is expected to miss its COVID-19 vaccine supply target to the European Union for the second quarter after millions of doses were banned for use in Europe over safety concerns, an EU Commission spokesman said.
The setback could cause new delays to the bloc's vaccination drive, although the EU is relying mostly on the Pfizer-BioNTech (PFE.N), (22UAy.DE) shot to inoculate its population. More than half of adults in the EU have received at least one shot.
The European Medicines Agency (EMA) last week said J&J doses sent to Europe from an Emergent (EBS.N) factory in the United States would not be used as a precaution after a case of contamination with substances used for AstraZeneca (AZN.L) shots, which are also manufactured in that factory.
EMA said in a statement to Reuters that 17 million doses had been banned from use in the bloc after that decision.
"Following the non-release of these batches, the company is not expected to be in a position to deliver 55 million doses by the end of this quarter," Stefan De Keersmaecker, the EU commission spokesman on health, said on Wednesday.
The EU has ordered a total of 200 million doses from J&J, of which 55 million were to be delivered by the end of June. The company has so far delivered around 12 million shots of its single-dose vaccine, of which only about half have been administered, EU figures show.
The spokesman declined to say how many doses J&J was now expected to deliver by the end of June.
"The member states and the Commission have voiced their strong concerns regarding this shortfall," he told a news conference, adding that the EU continued to work with the company "towards the delivery of the agreed doses overall in this and following quarters".
Despite the possible delays that this may cause, the spokesman said the EU remained on track to meet its target of immunising 70% of its adult population this summer.
"Johnson & Johnson remains committed to supplying 200 million doses of its COVID-19 vaccine to the European Union, Norway and Iceland and will continue to update the European Commission and member states in a timely manner as we refine delivery timelines," J&J said in a statement.
EU regulators have prevented the use in Europe of the 17 million potentially contaminated J&J doses but this does not necessarily mean their export is forbidden.
After having vaccinated large parts of their populations, wealthy nations are pledging to boost inoculations in poorer states, where new highly contagious variants could develop more easily if the virus is allowed to circulate freely.
EMA said it was not within its remit to order J&J to dispose of its potentially compromised vaccines.
But in a recommendation to the drugmaker, EMA made clear that if J&J decided to redirect the discarded doses to other markets, it "must be transparent with potential buyers about the underlying quality issues," EMA said in a statement on Wednesday.
J&J said that "out of an abundance of caution, the company will not release specific batches of its COVID-19 vaccine produced with drug substance manufactured by Emergent BioSolutions".
However, the company declined to comment on whether this decision will also cover the doses blocked in the EU. The U.S regulator has forbidden the use in the United States of tens of millions of J&J doses because of the same safety concerns.
At a global health summit in May, J&J said it would deliver 200 million doses to COVAX, the programme co-led by the World Health Organization (WHO) to distribute vaccines globally, which has so for delivered only about 90 million vaccines of the 2 billion planned this year.
Reporting by Francesco Guarascio @fraguarascio Editing by Catherine Evans
Our Standards: The Thomson Reuters Trust Principles.
More from Reuters
Play video on original page
Read Next
Asia Pacific
Vietnam health ministry reports 7,455 coronavirus infections on Monday
5:09 AM PDT
Middle East
Blast and financial crisis weigh heavily on mental health of Lebanese
4:50 AM PDT
Healthcare & Pharmaceuticals
What you need to know about the coronavirus right now
4:48 AM PDT
Asia Pacific
Malaysia reports record 219 COVID-19 deaths on Monday
4:32 AM PDT

Sign up for our newsletter
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Healthcare & Pharmaceuticals
Healthcare & Pharmaceuticals · 3:40 AM PDT
Delta spreads 'like wildfire' as doctors study whether it makes patients sicker 
With a new wave of COVID-19 infections fueled by the Delta variant striking countries worldwide, disease experts are scrambling to learn whether the latest version of coronavirus is making people - mainly the unvaccinated - sicker than before.
Healthcare & Pharmaceuticals
Australia tightens COVID curbs as Brisbane extends lockdown, army patrols Sydney
3:36 AM PDT
Healthcare & Pharmaceuticals
Philippines to extend night curfew in Manila amid COVID-19 surge
2:33 AM PDT
Healthcare & Pharmaceuticals
Republican report says coronavirus leaked from China lab; scientists still probing origins
August 1, 2021
Healthcare & Pharmaceuticals
Thailand steps up home isolation as virus cases strain hospitals
3:32 AM PDT
About Reuters
About Reuters
Reuters News Agency
Brand Attribution Guidelines
Reuters Leadership
Reuters Fact Check
Reuters Diversity Report
Stay Informed
Download the App
Information you can trust
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Follow Us
Thomson Reuters Products
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Refinitiv Products
Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface.
Refinitiv Data Platform
Access to real-time, reference, and non-real time data in the cloud to power your enterprise.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
Advertise With Us
Advertising Guidelines
Terms of Use
Site Feedback

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved